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Rhabdomyosarcoma (RMS), a tumor of skeletal muscle origin, is the most common sarcoma of childhood. Despite
multidrug chemotherapy regimens, surgical intervention, and radiation treatment, outcomes remain poor,
especially in advanced disease, and novel therapies are needed for the treatment of these aggressive
malignancies. Genetically engineered oncolytic viruses, such as herpes simplex virus-1 (HSV), are currently being
explored as treatments for pediatric tumors. M002, an oncolytic HSV, has both copies of the γ134.5 gene deleted,
enabling replication in tumor cells but thwarting infection of normal, postmitotic cells. We hypothesized that M002
would infect human RMS tumor cells and lead to decreased tumor cell survival in vitro and impede tumor growth
in vivo. In the current study, we demonstrated that M002 could infect, replicate in, and decrease cell survival in
both embryonal (ERMS) and alveolar rhabdomyosarcoma (ARMS) cells. Additionally, M002 reduced xenograft
tumor growth and increased animal survival in both ARMS and ERMS. Most importantly, we showed for the first
time that repeated dosing of oncolytic virus coupled with low-dose radiation provided improved tumor response in
RMS. These findings provide support for the clinical investigation of oncolytic HSV in pediatric RMS.
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Rhabdomyosarcoma (RMS), a malignant neoplasm of striated
muscle, is the most common soft tissue sarcoma of childhood.
There are two peaks in incidence, between the ages of 2 to 4 and 12 to
16 years, with the majority diagnosed by age 14 years [1]. The most
common primary sites include the head, neck, genitourinary tract,
and extremities [2]. The World Health Organization categorizes
RMS into embryonal, alveolar, spindle/sclerosing, and pleomorphic
subtypes, with embryonal RMS accounting for over 70% of cases and
representing the most favorable prognosis [3]. The 5-year survival rate
in children diagnosed with low-risk RMS is over 90%. Those with
metastatic or recurrent disease, however, fare much worse, with a
5-year survival of only 10% to 20% despite aggressive multimodal
therapies [4,5]. This is the group which must be targeted for novel
therapies.The Intergroup Rhabdomyosarcoma Study Group, created in
1972, established clinical trials and standard protocols in efforts to
improve outcomes and survival [2]. Current treatment regimens for
high-risk RMS include surgery, chemotherapy, and radiation therapy
[6]. Oncolytic viruses are currently being explored as treatments for
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herpes simplex virus (oHSV) with both copies of the γ134.5 gene
deleted [9] to decrease neurovirulence [10]. M002 has been shown to
have efficacy in pediatric brain tumor [11] and other pediatric solid
tumor models [12,13].
These previous results led us to hypothesize that treatment with
M002 would result in decreased RMS tumor cell survival in vitro and
impede tumor growth in vivo in an immunocompromised murine
model of RMS. Our studies confirmed that M002 had significant
cellular effects on two RMS cell lines, including both an embryonal
and alveolar model, and decreased RMS xenograft growth in vivo. In
addition, we have shown for the first time that repeated dosing of an
oncolytic virus in combination with irradiation has improved efficacy
over single dosing in RMS.
Materials and Methods
Cells and Cell Culture
All cell lines were maintained in standard culture conditions at
37°C and 5% CO2. RD human embryonal RMS (ERMS) cells
(CCL-136; American Type Culture Collection [ATCC], Manassas,
VA) were maintained in Dulbecco's modified Eagle's medium
containing 10% fetal bovine serum, 4 mM L-glutamine, 1 μM
nonessential amino acids, and 1 μg/ml of penicillin/streptomycin.
SJCRH30 human alveolar RMS (ARMS) cells (CRL-2061, ATCC)
were maintained in RPMI 1640 medium supplemented with 10%
fetal bovine serum and 1 μg/ml of penicillin/streptomycin. Vero
(ATCC CCL-81, monkey kidney) cells were maintained in Eagle's
minimum essential medium with 10% fetal bovine serum. All cell
lines were purchased within the last 18 months and were mycoplasma
free.
Virus
A genetically engineered oncolytic herpes simplex virus, M002, has
been previously described [9]. Briefly, R3659 was the parent virus for
M002 with the thymidine kinase gene inserted into deleted regions of
both γ134.5 loci and a deletion in the native thymidine kinase locus.
M002 is a conditionally replication-competent mutant herpes
simplex virus expressing both subunits of murine interleukin-12
(mIL-12) under the transcriptional control of the murine
early-growth response-1 promoter; two copies of the entire construct
are present, with a single copy inserted into each of the γ134.5 loci;
the native thymidine kinase gene is restored. To titer the M002 virus,
Vero cells were plated in 24 well plates at 1.5 × 105 cells per well and
allowed 24 hours to attach and form a confluent monolayer. Ten-fold
dilutions of stock virus in infection medium (1% FBS in Dulbecco's
modified Eagle's medium/F12) were applied to the Vero cells for 2
hours, the inoculum was removed, and the plates were washed with
media. After 48 hours of incubation, May-Grunwald stain in
methanol was applied for 20 minutes, and plates were washed and
dried overnight. Plaques were counted, and the titer was calculated
and reported as plaque-forming units per milliliter (PFU/ml).
Viral Replication
Viral recovery experiments were performed as described previously
[12,13]. For single-step viral recovery, RD and SJCRH30 cells were
plated and allowed to attach for 24 hours. The cells were infected with
M002 at a multiplicity of infection (MOI) of 10 PFU/cell for 2 hours.
After 12 and 24 hours, the cells were harvested by adding equal
volume of sterile milk and freezing at −80°C. Plates were thawed at37°C and underwent two more freeze/thaw cycles. Cells and
supernates were collected, milk stocks were sonicated for 30 seconds,
and the titers of progeny virions were determined on Vero cell
monolayers. The average PFU/ml was calculated from quadruplicate
wells.
For multistep viral recovery experiments, RD and SJCRH30 cells
were grown to confluence in six-well plates and then infected with
M002 at an MOI of 0.1 PFU/cell. The media from the cells were
harvested at 6, 24, 48, and 72 hours postinfection. The titers of
progeny virions in the supernate were determined as above, and the
average PFU/ml was calculated from quadruplicate wells.
ELISA
Production of mIL-12 by the recombinant M002 virus was
quantified using a total mIL-12 ELISA kit (Thermo Fisher Scientific,
Rockford, IL). Ninety-six–well plates were seeded with 1.5 × 104
cells per well for 24 hours and then treated with media alone or
M002. After incubating for 48 hours, the supernates were collected
and analyzed by ELISA according to the manufacturer's protocol.
Virus Cytotoxicity Assays
Cell viability 72 hours after virus treatment in vitro was measured
using an alamarBlue assay. Cells were plated (1.5 × 103 cells/100-μl
well) in 96-well culture plates and after 24 hours were treated with
100 μl of saline or a graded series of dilutions of M002. After 72
hours of culture, 10 μl of sterile alamarBlue dye (Invitrogen Life
Technologies, Grand Island, NY) was added to each well. After 4 to 6
hours, the absorbance at 542 and 595 nm was measured using a
kinetic microplate reader (BioTek Gen5; BioTek Instruments,
Winooski, VT). Virus cytotoxicity at each dilution was measured
by the reduction in the color change compared with that seen in the
saline treatment group (100%) viability. These values were plotted to
yield an estimate of the PFU of M002 required to inhibit 50% of the
cells by 72 hours (IC50/PFU).
Antibodies
Antibodies used for Western blotting were as follows: rabbit
polyclonal anti-PVRL-1 (CD111) from Abcam (ab71512; Abcam,
Cambridge, MA); rabbit polyclonal anti-nectin 2 (CD112) from
Bioss (bs2679R; Bioss Inc., Woburn, MA); rabbit polyclonal
anti-syndecan-2 from LS Biosciences (LS-B2981; LifeSpan Biosci-
ences, Inc., Seattle, WA); rabbit polyclonal anti-phospho Stat1
(Y701, 9171S), anti-Stat1 (9172S), mouse monoclonal anti-phospho
p38 mitogen-activated protein kinase (MAPK) (Thr180/Tyr182,
9216S), and rabbit polyclonal anti-PARP (9542S) from Cell
Signaling (Cell Signaling Technology, Inc., Danvers, MA); and
rabbit polyclonal anti-p38 (H-147, sc-7149) from Santa Cruz (Santa
Cruz Biotechnology Inc., Santa Cruz, CA). Mouse monoclonal
anti–β-actin (a1978) was purchased from Sigma (Sigma-Aldrich, St.
Louis, MO).
Western Blotting
Western blots were performed as previously described [14]. Cells
were lysed on ice for 30 minutes in a buffer containing 50 mM Tris–
HCL (pH 7.5), 150 mM NaCl, 1% Triton-X, 0.5% NaDOC, 0.1%
SDS, 5 mM EDTA, 50 mMNaF, 1 mMNaVO3, 10% glycerol, and
protease inhibitors: 10 μg/ml of leupeptin, 10 μg/ml of PMSF, and
1 μg/ml of aprotinin. The lysates were cleared by centrifugation at
14,000 rpm for 30 minutes at 4°C. Protein concentrations were
determined using a Bio-Rad kit (Bio-Rad, Hercules, CA), and
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Antibodies were used according to manufacturers' recommended
conditions. Molecular weight markers (Bio-Rad) were used to
confirm the expected size of the target proteins. Immunoblots were
developed with chemiluminescence (Amersham ECL; GE Healthcare
Biosciences, Pittsburgh, PA). Blots were stripped with stripping
solution (Bio-Rad) at 37°C for 15 minutes, rinsed, and then reprobed
with selected antibodies. Immunoblotting with antibody to
anti–β-actin provided an internal control for equal protein loading.
Apoptosis
Cellular apoptosis was detected with two methods; immunoblot-
ting for PARP cleavage and a commercially available colorimetric
caspase 3 activation kit (KHZ0022; Invitrogen, Life Technologies,
Thermo Fisher Scientific, Inc.). For immunoblotting, cells were
treated with increasing MOI of M002 and whole cell lysates utilized
for SDS-PAGE. Membranes were probed with appropriate antibodies
with β-actin serving as an internal control for equal protein loading.
Increasing intensity of PARP bands for cleaved products combined
with decreasing intensity of bands for total PARP indicated apoptosis.
Additionally, activation of caspase 3 was also measured with a kit,
according to manufacturer's instructions.
Immunohistochemistry
Human specimens were obtained following institutional review
board (IRB) approval (X100930009) under a waiver of informed
consent, and all experiments were carried out in accordance with the
IRB-approved guidelines. Formalin-fixed, paraffin-embedded tumor
blocks of murine xenografts or human RMS specimens were cut in
8-μm sections. The slides were baked for 1 hour at 70°C,
deparaffinized, rehydrated, and steamed. The sections were then
quenched with 3% hydrogen peroxide and blocked with
PBS-blocking buffer. The primary rabbit polyclonal antibody, anti–
herpes simplex virus type I antibody (1:250, PU084-UP; BioGenex,
Fremont, CA), or primary mouse polyclonal anti-CD111 antibody
(1:300, ab66985, Abcam) was added and incubated overnight at 4°C.
After washing the HSV slides with PBS, the Superpicture anti-rabbit
HRP secondary antibody (Life Technologies, Inc., Grand Island, NY)
was added at 1:250 dilution for 1 hour at 22°C. The staining reaction
was developed with VECTASTAIN Elite ABC kit (PK-6100; Vector
Laboratories, Burlingame, CA), TSA (biotin tyramide reagent, 1:400;
PerkinElmer, Inc., Waltham, MA), and DAB (Metal Enhanced DAB
Substrate; Thermo Fisher Scientific). For the CD111 slides, after
washing with PBS, the Super Sensitive Polymer-HRP Detection Kit
with DAB (QD400-60K; Biogenex, Fremont, CA) was utilized for
detection of the antigen-antibody binding. Slides were counterstained
with hematoxylin. A negative control (rabbit IgG or mouse IgG,
1 μg/ml [Millipore, EMD Millipore, Billerica, MA]) was included
with each experiment. For hematoxylin and eosin staining, slides were
cut and baked as described above, and standard hematoxylin and
eosin staining methods were utilized.
Immunohistochemistry Scoring
Staining for HSV-1 in xenograft tumors was quantified by ImageJ
software (http://rsb.info.nih.gov/ij/). Positive HSV-1 staining was
reported as percent positive staining cells per high-power field after
counting 10 random fields of view per specimen. CD111 staining in
human RMS specimens was quantified by pathologist (S. M.) blinded
to the specimens. Specimens were scored based upon the intensity ofstaining and the percentage of tumor cells staining. Intensity was
graded from 0 to 3 (0, none; 1, weak; 2, moderate; 3, strong) and
multiplied by the percentage of cells with that staining. For example,
if the specimen showed moderate staining (2) in 40% of the cells, the
stain score would be 80 (2 × 40 = 80).
Tumor Growth In Vivo
Animal experiments were completed following institutional
institutional animal care and use committee (IACUC) approval
(IACUC-09363). Six-week-old female athymic nude mice were
purchased from Harlan Laboratories, Inc. (Chicago, IL). The mice
were maintained in the specific pathogen free (SPF) animal facility
with standard 12-hour light/dark cycles and allowed chow and water
ad libitum. All experiments were carried out in accordance with the
approved guidelines, and at the completion of the experiments,
euthanasia was accomplished according to American Association for
Laboratory Animal Science guidelines utilizing compressed CO2 gas in
their home cage followed by bilateral thoracotomy. Human RMS cells,
RD (2.5 × 106 cells), and SJCRH30 (2.0 × 106 cells) in Matrigel (1:1
dilution with sterile PBS, volume 100μl; BDBiosciences, San Jose, CA)
were injected subcutaneously into the right flank. Once tumors reached
approximately 250 mm3, animals (n = 40) were randomized to receive
an intratumoral injection of vehicle (PBS + 10% glycerol, 50 μl) or
M002 virus (1 × 107 PFU/50 μl) (n = 20). These concentrations were
chosen based upon previous investigations with the virus [9,12,13].
Within 6 hours of treatment, half of the vehicle-treated tumors and half
of the M002-treated tumors received a low dose of external beam
irradiation (3 Gy) directed at the flank tumor (n = 10 animals/group).
Previous studies have demonstrated the enhanced oncolytic effects of
viral therapy when combined with radiation [15]. Tumors were
measured twice weekly with a caliper, and tumor volume in mm3 was
calculated using a standard formula [(width2 × length)/2], where width
was the smaller diameter. Once tumors reached the size predetermined
by IACUC protocol standards, the animals were euthanized, and the
tumors were harvested and processed for study.
For the repeated-dosing study, ARMS SJCRH30 cell line was
chosen because ARMS tends to be more difficult to treat than ERMS.
SJCRH30 (2.0 × 106) cells in Matrigel (1:1 dilution with sterile PBS,
volume 100 μl; BD Biosciences) were injected subcutaneously into
the right flank of 6-week-old female nude mice (n = 20). Once tumors
reached approximately 250 mm3, animals were randomized to receive a
single intratumoral injection ofM002 virus (1 × 107 PFU/50μl) (n = 6)
or an additional two intratumoral doses of virus (1 × 107 PFU/50 μl,
total of three doses) at 3-day intervals with (n = 7) or without the addition
of low-dose flank irradiation (XRT) (n = 7) following the virus injection.
Tumors were measured twice weekly with a caliper, and tumor volume in
mm3 was calculated using a standard formula [(width2 × length)/2],
where width was the smaller diameter. Once tumors reached the
size predetermined by IACUC protocol standards, the animals
were euthanized.
Data Analysis
Experiments were repeated at least in triplicate, and data are
reported as mean ± standard error of the mean. An analysis of
variance or Student's t test was used as appropriate to compare data
between groups, and log-rank test was used to determine survival
significance. Statistical analyses were completed using SigmaPlot 12
software (SyStat Software, Inc., San Jose, CA) with statistical
significance determined at the P ≤ .05 level.
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HSV Entry Receptors and Viral Infectivity
Two different histologic subtypes of RMS were chosen for study:
ERMS (RD) and ARMS (SJCRH30) [16]. CD111 (poliovirus
receptor-related protein 1 [nectin-1]) is a cell surface receptor that is
the primary viral entry mediator used by HSV-1 for cellular entry
[17]. Immunoblotting with CD111 specific antibody detected
CD111 protein in whole cell lysates of SJCRH30 and RD RMS
cells lines (Figure 1A). Two additional virus entry receptors were also
investigated. It has been reported in the literature that certain
laboratory strains of HSV-1 may use CD112 (poliovirus
receptor-related 2, nectin-2) as another receptor for cell entry
[18,19], so we also examined cell lysates for this protein and found
that CD112 was also expressed by the SJCRH30 and RD cell lines
(Figure 1B). Additionally, heparin sulfate proteoglycan (syndecan-2)
is another protein known to play an important role in HSV-1 viral
entry and spread [20]. Cell lysates from SJCRH30 and RD cells were
examined with immunoblotting and found to have syndecan-2
protein present (Figure 1C). These data indicated that these cell lines
had the receptors necessary for HSV-1 viral entry and infection.
In anticipation of advancing to human studies and to provide a
rationale for clinical application of oHSV for RMS, we determinedFigure 1. HSV entry receptors in cell lines and human RMS specim
specific antibodies demonstrated all three proteins to be present in w
was used to confirm equal protein loading. Immunohistochemical stai
Representative photomicrographs at 10× and 40× are presented. The
both histologic types. Negative controls reacted appropriately (bottowhether CD111 protein was present in human RMS specimens.
Following IRB approval (X100920009) under a waiver of informed
consent, we performed CD111 immunostaining on human ERMS
(n = 12) and ARMS (n = 10) specimens. The CD111 staining was
scored by a pathologist (S. M.) blinded to the specimens, and the
mean stain scores were compiled based upon stain intensity. CD111
staining was positive in all of the specimens examined, with a mean
stain score of 89 ± 2% in ARMS and 91 ± 1% in ERMS specimens.
Representative photomicrographs were presented at 10× and 40×
(Figure 1, D and E). There was cell surface CD111 staining in both
tumor types (Figure 1, D and E, black arrows), and negative controls
(rabbit IgG) reacted appropriately (Figure 1, D and E, small box
inserts).
To ascertain whether M002 could infect and replicate in the RMS
cell lines, in vitro replication of M002 was evaluated in the RD and
SJCRH30 cell lines using single- and multistep viral recovery
experiments. For the single-step experiments, the RD and SJCRH30
cell lines were infected with M002 at an MOI of 10 PFU/cell. By 24
hours postinfection, there were significant viral titers noted in both
cell lines (Figure 2A) that continued to increase at 48 hours
postinfection (Figure 2A). For multistep viral recovery, monolayers of
RD and SJCRH30 cell lines were infected with M002 at an MOI of
0.1 PFU/cell, and at 6, 24, 48, and 72 hours postinfection, viralens. (A–C) Immunoblotting with CD111, CD112, and syndecan-2
hole cell lysates of SJCRH30 and RD human RMS cell lines. β-Actin
ning was performed on human ARMS (D) and ERMS (E) specimens.
re was CD111 staining present on the cell surface (black arrows) in
m left inserts, D, E).
Figure 2. Infectivity of M002 in RMS cell lines. (A) Single-step in vitro replication of M002. Monolayers of RD and SJCRH30 cells were
infected with M002 at an MOI of 10 PFU/cell. Replicate cultures were harvested at 24 and 48 hours postinfection, and virus titers were
determined on Vero cell monolayers. Mean virion yields were determined in four replicates at each time point, and standard error of the
mean was determined. By 24 hours postinfection, there were significant viral titers noted in both cell lines that continued to increase at 48
hours postinfection. (B) Multistep replication of M002. Monolayers of RD and SJCRH30 cells were infected with M002 at an MOI of
0.1 PFU/cell, and at 6, 24, 48, and 72 hours postinfection, supernates were collected, and virus titers were determined on Vero cell
monolayers. Mean virion yields were determined in four replicates at each time point, and standard error of the mean was determined. In
the RD cell line, M002 replicated more than a log higher than control at 72 hours postinfection, and in the SJCRH30 cell line, replication of
virus was more than 3 logs greater than time zero. (C) Because M002 was engineered to produce mIL-12, to further verify infection,
mIL-12 production was determined in RD and SJCRH30 cell lines following treatment with M002 oHSV. Cell lines were infected with
M002 at 0, 0.1, or 1.0 PFU/cell. At 48 hours postinfection, the supernates were collected, and concentrations of mIL-12 were determined
by ELISA. Data are reported asmean ± standard error of themean. There was a significant increase inmIL-12 production in both cell lines
even with the lower MOI of virus.
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infection, M002 replicated to a titer significantly higher in both cell
lines compared with that of time zero.
Because M002 was genetically engineered to produce mIL-12, to
further verify viral infection, we sought to determine the extent to
which the infected human RMS cell lines would produce the encoded
foreign mIL-12 protein. The RD and SJCRH30 cells were infected
with M002 at 0, 0.1, or 1.0 PFU/cell. After 24 hours of infection, the
supernates were collected, and an mIL-12 ELISA kit was utilized to
detect IL-12 production. There were significant increases in mIL-12
after M002 infection of both RMS cell lines (Figure 2C), confirming
infection and virus replication in both cell lines. In the RD cell line,
infection with 0.1 PFU/cell for 24 hours resulted in a concentration
of mIL-12 of 2486 ± 100 pg/ml, significantly greater than the
concentration after infection with 0 PFU/cell (control, 0.0 pg/ml,
P = .002) (Figure 2C). Similar findings were seen with the
SJCRH30 cell line; infection with 0.1 PFU/cell for 24 hours resulted
in a concentration of mIL-12 of 1194 ± 265 pg/ml, significantlygreater than concentration of 0.0 pg/ml after infection with 0 PFU/cell
(control, P = .04) (Figure 2C). In addition, in the SJCRH30 alveolar
cell line, increasing the MOI of the M002 oHSV by a factor of 10
resulted in a statistically significant increase in the production of
mIL-12 compared with the lower MOI (1194 ± 265 pg/ml vs 5036 ±
636 pg/ml, 0.1 PFU/cell vs 1.0 PFU/cell, P = .03). Previous studies
from our group have shown that the parent virus, devoid of mIL-12
insertion, does not stimulate mIL-12 production in human cell lines
[9]. The ELISA studies were utilized only to verify virus infection.
Treatment with M002 Resulted in Cell Death
RMS cell lines (RD, SJCRH30) were treated for 72 hours with
M002 at increasing concentrations (0-20 PFU/cell), and cell viability
was measured with alamarBlue assays. Both cell lines had a significant
decrease in viability following M002 treatment (Figure 3A). The
lethal dose of virus that resulted in 50% killing (LD50) for the
embryonal RD cells was 3.3 ± 0.1 PFU/cell and for the alveolar
SJCRH30 cells was 4.1 ± 0.4 PFU/cell.
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to apoptosis. RD and SJCRH30 cell lines were treated with increasing
concentrations of M002 (0-10 PFU/cell), and whole cell lysates were
collected after 72 hours of treatment. Lysates were studied with
immunoblotting to detect cleavage of PARP. The decrease in total
PARP, accompanied with an increased in the cleaved PARP product,
indicated that the RMS cells were undergoing apoptosis. This finding
was evident in both cell lines (Figure 3B). Apoptosis was confirmed
using a caspase 3 activation kit. There was a significant increase in
caspase 3 activation in the SJCRH30 cell line at 0.1 PFU/cell and in
the RD cell line at MOI of 10 PFU/cell (Figure 3C), similar to the
results seen in the PARP immunoblotting, indicating an apoptotic
process.
In Vivo Tumor Studies
All experiments were performed in accordance with relevant
guidelines and regulations after IACUC approval (IACUC-09,363).
To determine the in vivo effects of M002 treatment on RMS, nude
mouse xenograft models were utilized. RD human ERMS cells
(2.5 × 106 in Matrigel [BD Biosciences]) were injected subcutane-
ously into the right flank of female athymic nude mice (n = 40).
Once flank tumors reached an average volume of 250 mm3, theFigure 3. Treatment with M002 resulted in cell death. (A) RD and SJC
hours of treatment, cell viability was measured with alamarBlue assa
was a significant decrease in viability in both cell lines following M002
was 3.3 ± 0.1 PFU/cell for embryonal RD cells and 4.1 ± 0.4 PFU/cell
were undergoing an apoptotic process following M002 treatment, im
significant decrease in total PARP staining and an increase in cleaved
verify apoptosis, a caspase 3 activation kit was utilized. There was a sig
indicating that the RMS cells were undergoing an apoptotic processtumors were injected with either control vehicle (PBS + glycerol,
50 μl, n = 20) or a single dose ofM002 (1 x× 107 PFU/50 μl, n = 20).
Because the addition of low dose radiation has been shown to increase
the activity of oHSV in malignant gliomas [15,21,22], we examined
whether the addition of a single low dose of radiation would also
enhance the efficacy of M002 in the RD xenografts. Therefore, half of
the animals in each group received a low dose of irradiation to the tumor
immediately following injection with vehicle or M002. Three grays
(3 Gy, XRT) was chosen because other investigations have shown that
HSV replication increased in a dose-dependent fashion following
irradiation with 2 to 5 Gy, with no additional effects seen after 5 Gy
[22]. Tumor volumes were measured biweekly with calipers. Tumor
volumes were followed 40 days, when most of the vehicle-treated
animals had been euthanized as dictated by IACUC protocol. In the
animals treated withM002 and XRT, there was a significant decrease in
tumor growth beginning at day 19 and continuing to 40 days when
compared with the animals in the vehicle or vehicle + XRT treatment
groups (P ≤ .05) (Figure 4A). Tumor volumes in the M002 + XRT
were also smaller than those from M002 alone but did not reach
statistical significance. The addition of low-dose (3 Gy) XRT to the
vehicle treatment did not significantly affect tumor growth when
compared with vehicle alone (Figure 4A). Animals were followed forRH30 cell lines were treated with M002 at increasing MOI. After 72
ys. Data are reported as mean ± standard error of the mean. There
treatment. The LD50 was calculated for each cell line for M002 and
for the alveolar SJCRH30 cells. (B) To determine whether RMS cells
munoblotting for cleavage of PARP was completed. There were a
PARP staining in both cell lines with increasing MOIs. (C) To further
nificant increase in caspase 3 activation followingM002 treatment,
.
Figure 4.M002 treatment of RD xenografts. (A) RD human RMS tumor cells (2.5 × 106 cells) were injected into the right flank of athymic
nude mice. Once tumors reached a volume of 250 mm3, animals received an intratumoral injection of vehicle (PBS+ 10% glycerol, 50 μl
[n = 20]) or M002 virus (1 × 107 PFU/50 μl [n = 20]). Half of the animals in each group also received low-dose irradiation (3 Gy) at the time
of injection. Tumor volumes were measured twice weekly [(width)2 × length]/2 for 40 days. Data are reported as tumor volume ±
standard error mean. In the animals treated with M002 and XRT, there was a significant decrease in tumor growth beginning at day 19
when compared with the animals in the vehicle or vehicle + XRT treatment groups. Tumor volumes in theM002 + XRT were also smaller
than those from M002 alone, but this did not reach statistical significance. The addition of low-dose (3 Gy) XRT to the vehicle treatment
did not significantly affect tumor growth (Figure 3A). (B) Xenograft tumors were weighed at euthanasia. There was a significant decrease
in tumor weight in the animals treated with M002 and XRT when compared with animals that received vehicle alone or vehicle with XRT.
Tumor weights in M002 + XRT group tended to be less than those of M002 alone but did not reach statistical significance. Lines in bars
represent the median, and the whiskers represent the 5th and 95th percentile. (D) Kaplan-Meier curves were constructed with log-rank
statistics to evaluate animal survival. Animals treated with M002 had significantly increased survival over those treated with vehicle alone.
Animals treated with M002 + XRT also had a significant survival advantage when compared with those treated with vehicle or vehicle
+XRT.
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xenograft tumors treated with M002 + XRT weighed significantly less
than those treated with vehicle or vehicle + XRT (1.9 ± 0.3 g vs 3 ± 0.3
g or 2.8 ± 0.3 g, M002 + XRT versus vehicle or vehicle + XRT,
P ≤ .02) (Figure 4B). The M002 + XRT tumors also weighed less
than those treated with M002 alone but, similar to tumor volume,
did not reach significance (Figure 4B). There were some differences
in the final weights of the animals at the time of euthanasia, but
these were not statistically significant (Figure S1A). To exclude animal
growth as an explanation for differences in tumor weights, tumor
to body weight ratios at the time of animal euthanasia were
calculated. These ratios (Figure S1B) were consistent with the data
seen with tumor weights alone, discounting animal growth as a factor in
tumor weight differences. As seen in Figure 4C, the animals treated with
M002 had significantly increased survival when compared withvehicle-treated animals (36.3 ± 3.0 vs 27.2 ± 2.1 days, M002 versus
vehicle, P = .017). In addition, animals treated with M002 + XRT
had significantly increased survival over those treated with vehicle or
vehicle + XRT (Figure 4C).
The second set of in vivo experiments examined the effects of
M002 upon SJCRH30 ARMS xenografts. SJCRH30 cells (2.0 × 106
cells in Matrigel [BD Biosciences]) were injected into the
subcutaneous space of the right flank of female nude mice (n =
40). Once xenografts reached 250 mm3, tumors were injected with
vehicle (PBS + glycerol, 50 μl, n = 20) or a single dose of M002
(1 × 107 PFU/50 μl, n = 20). Half of the animals in each group
received a single low dose of external beam irradiation (3 Gy, XRT) to
the tumor as described above. Tumor volumes were followed for 41
days when most of the vehicle-treated animals had been euthanized
per IACUC protocol. Animals treated with M002 + XRT had
Figure 5.M002 treatment of SJCRH30 xenografts. (A) SJCRH30 cells (2.0 × 106 cells) were injected into the subcutaneous space of the
right flank of female nude mice (n = 40). Once tumors reached 250 mm3, animals received an intratumoral injection of vehicle
(PBS+ 10% glycerol, 50 μl [n = 20]) or M002 virus (1 × 107 PFU/50 μl [n = 20]). Half of each group was also treated with 3-Gy external
beam radiation at the time of injection (XRT). Tumor volumes were measured twice weekly and reported as tumor volume ± standard
error. Beginning on day 23, there was a significant decrease in tumor volume in the animals treated with combined M002 + XRT. (B)
Xenograft tumors were weighed at euthanasia. There was a significant decrease in tumor weight in the animals treated with M002 and
XRT when compared with animals that received vehicle with XRT. Lines in bars represent the median, and the whiskers represent the 5th
and 95th percentile. (C) Kaplan-Meier curves were constructed with log-rank statistics to examine animal survival. Animals treated with
M002 had significantly increased survival over those treated with vehicle alone. Animals treated with M002 + XRT also had a significant
survival advantage when compared with those treated with vehicle or vehicle and XRT.
426 Repeated M002 Dosing Decreases RMS Survival Waters et al. Translational Oncology Vol. 9, No. 5, 2016significantly smaller tumor volumes than the animals from the
other three treatment groups, including M002 alone (Figure 5A).
The addition of low-dose (3 Gy) XRT to the vehicle treatment did
not affect SJCRH30 tumor growth compared with vehicle alone
(Figure 5A). The animals remaining were followed for survival. At
euthanasia, tumors were harvested and weighed. M002 + XRT–
treated SJCRH30 xenografts tended to weigh less than those of the
other treatment groups, but this difference reached statistical
significance only when compared with the vehicle + XRT treatment
group (Figure 5B). As seen with the RD xenografts, there were some
differences in the final weights of the animals at the time of
euthanasia, but these were not statistically significant (Figure S1C).
Tumor to body weight ratios at the time of animal euthanasia were
calculated, and these ratios (Figure S1D) were consistent with the data
seen with tumor weights alone, discounting animal growth as a factor
in tumor weight differences. Animals treated with M002 alone had
improved mean survival over animals treated with vehicle alone(41.4 ± 3.6 vs 32.3 ±2.7 days, M002 versus vehicle, P = .05) as
depicted in Figure 5C. Furthermore, animals treated with
M002 + XRT had an increase in survival over those treated with
vehicle alone or with vehicle + XRT (Figure 5C). The notable
decreases in tumor volume with the addition of XRT to M002
treatment (Figure 5A) did not translate into statistically improved
survival advantage over M002 alone (54.4 ± 7.3 vs 41.4 ± 3.6 days,
P = .3, M002 + XRT versus M002, Figure 5C). In both cell types,
tumor growthwas significantly decreased but not completely abrogated.
The presence of HSV in the tumors following treatment was
verified with immunohistochemical staining for HSV-1. Represen-
tative photomicrographs are presented in Figure 6. Immunohisto-
chemical staining for HSV-1 detected virus in tumors injected with
M002 (Figure 6, middle panel brown stain, white arrows) and with
M002 + XRT (Figure 6, lower panel brown stain, white arrows) for up
to 7 days post virus injection. There was a lack of staining in tumors
injected with vehicle (Figure 6, upper panel). Negative controls
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lower panels). Immunohistochemical staining was quantified with
ImageJ software. There was a slight increase in the amount of positive
staining at 7 days postinfection when comparing tumors treated with
M002 + XRT versus those treated with M002 alone, but this finding
was not statistically significant.Figure 6. Histological examinations of RMS xenografts for HSV. The p
immunohistochemical staining for HSV-1. Representative photomic
staining for HSV-1 detected virus in tumors injected with M002 (mi
panels brown stain, white arrows), present at 7 days post virus injecti
(upper panels). Negative controls reacted appropriately (insert, bottomBecause M002 did not result in a sustained response in decreasing
tumor growth, we advanced to a model of repeated dosing of virus.
We chose to study the SJCRH30 cell line because ARMS is clinically
more difficult to treat. SJCRH30 cells (2.0 × 106 cells in Matrigel
[BD Biosciences]) were injected into the subcutaneous space of the
right flank of female nude mice (n = 20). Once xenografts reachedresence of HSV in the tumors following treatment was verified with
rographs are at 20× (right) and 40× (left). Immunohistochemical
ddle panels brown stain, white arrows) and M002 + XRT (bottom
on. Tumors injected with vehicle did not demonstrate HSV staining
right, upper, middle, and lower panels).
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single intratumoral injection of M002 on day 0 (1 × 107 PFU/50 μl,
n = 6); 2) repeated intratumoral injection of M002 on days 0, 3, and
6 (1 × 107 PFU/50 μl, n = 7); or 3) repeated intratumoral injection
of M002 (1 × 107 PFU/50 μl) on days 0, 3, and 6 with low-dose
XRT (3 Gy) on those days (n = 7). Tumor volumes were measured
twice weekly and followed for 40 days when most of the single-dose
animals had been euthanized per IACUC protocol. Animals treated
with repeated doses of M002 had significantly smaller tumor volumes
than the animals that received only a single dose of virus (Figure 7).
Furthermore, animals that were given low-dose XRT in addition to
repeat M002 had smaller tumors than those that did not receive
additional XRT and those that had only a single intratumoral
injection of M002 (Figure 7).
STAT1 and p38 MAPK
We investigated possible mediators of sensitivity of the two RMS
cell lines to M002. Previous investigators have shown that
upregulation of STAT1 was associated with decreased response to
oHSV [23]. Other investigators have shown that decreased
phosphorylation of p38 was also associated with resistance to oHSV
and that increased activation of p38 MAPK was associated with
improved virus replication [21,23,24]. Therefore, to determine if
these proteins played a potential role in the difference in responses of
the cell lines to oHSV, immunoblotting was utilized to determine
their expression and phosphorylation. STAT1 activation did not
increase following M002 treatment in either cell line (Figure S2A),
and p38 phosphorylation appeared to increase with M002 treatment
in both cell lines (Figure S2B).Figure 7. Repeated injections of M002 in SJCRH30 xenografts.
SJCRH30 cells (2.0 × 106 cells) were injected into the subcutane-
ous space of the right flank of female nude mice (n = 20). Once
tumors reached 250 mm3, animals were randomized to three
groups: 1) single intratumoral injection of M002 virus (1 × 107
PFU/50 μl [n = 6]); 2) repeated intratumoral injection of M002
(1 × 107 PFU/50 μl) on days 0, 3, and 6 (n = 7); and 3) repeated
intratumoral injection of M002 (1 × 107 PFU/50 μl) followed by
low-dose irradiation (3 Gy, XRT) on days 0, 3, 6 and (n = 7). Tumor
volumes were measured twice weekly and reported as fold change
in tumor volume ± standard error. Beginning on posttreatment
day 18, the animals receiving multiple doses of M002 had
significantly less tumor growth than those treated with a
single dose. The animals treated with multiple doses of M002
and XRT had significantly less tumor growth than either the
single M002 dose or those that received multiple doses of M002
without XRT.Discussion
Despite therapeutic advances in the treatment of RMS, advanced
stage and recurrent tumors continue to carry a dismal prognosis with
little chance for long-term survival. Clearly, novel therapeutic
interventions are needed to combat this cancer, and various
virotherapies including vaccinia virus, picornavirus, and herpes
simplex viruses have been investigated as alternative treatments for
these tumors. He and colleagues utilized a recombinant vaccinia
oncolytic virus and demonstrated 40% cytotoxicity in the RMS cell
line HTB-82 7 days after infection with an MOI of 5 [8]. Others
examined the effects of Seneca Valley virus, NTX-010, against RMS.
Two of the four RMSs had an IC50 less than 1 virus particle per cell,
and NTX-010 inhibited the growth of four alveolar RMS xenografts
in vivo [25]. Data regarding the ability of oHSV to target human
RMS are sparse. Currier and colleagues studied the effects of a
first-generation mutated HSV (NV-1020) upon two RMS cell lines.
They found that with multiple injections of virus, the growth of both
ARMS and ERMS xenografts was significantly decreased [26].
Pressey et al. demonstrated that ARMS and ERMS cell lines
contained myogenically primitive cells marked by CD133 that had
cancer stem cell features and were resistant to several chemotherapy
agents but were sensitive to oHSV in vitro [27]. These previous
studies supported our investigations of the oHSV M002 in RMS.
Although virotherapy alone may be a viable therapeutic option for
RMS, modifications, such as the addition of exogenous cytokines,
could further contribute to the antitumor effects. The oHSV utilized
in these studies, M002, was encoded with the gene for mIL-12 [9],
and the levels of mIL-12 that were produced by both cell lines were
over several nanograms per milliliter. IL-12 is best known as a
cytotoxic T-lymphocyte and NK cell activator but also has antitumor
effects on RMS. Low serum levels of IL-12 have been correlated with
advanced disease, decreased response to chemotherapy, and poor
outcome in children with soft tissue sarcomas [28]. Schilbach and
others utilized humanized mice to study the effects of IL-12
administration upon human RMS and showed that treatment with
an antibody–IL-12 fusion protein arrested cancer cell proliferation
and induced myogenic differentiation in the tumors [29]. In the
current studies, we investigated oHSV on human RMS cell lines,
thereby requiring the use of immunodeficient mice. We were not able
to determine the immunologic effects of IL-12 in these xenografts
because these mice have negligible immune cells. The precise
contribution of IL-12 to the effects of oHSV seen upon RMS cell
lines in these studies will certainly be the subject of future
investigations.
A novel aspect of the current data is the documentation that both
ARMS and ERMS express the CD111 viral entry molecule, lending
credence to translating this therapy to the clinical setting. Another
important finding was that both ARMS and ERMS cell lines have
multiple oHSV viral entry receptors present. Although the expression
of CD111 in RMS cell lines has been documented [27], to our
knowledge, the demonstration of other important HSV entry
receptors has not been previously reported in the literature for these
cell lines. The relative expression of these receptors did not
significantly affect the ability of M002 to infect the cells. For
example, CD111 expression was less in the SJCRH30 compared with
the RD cell line, but single and multistep viral infection studies
demonstrated similar if not improved infection in the SJCRH30
compared with the RD cell line. In addition, despite lower levels of
CD111 protein in the SJCRH30 cell line, M002 was still very
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viral entry proteins such as CD112 and syndecan-2. These findings
are consistent with those seen recently with neuroblastoma. Wang
and colleagues found that the sensitivity of neuroblastoma cell lines to
and infectivity of HSV1716 were not dependent upon the entry
proteins or even viral entry itself [19].
We investigated the activation of STAT1 and p38 MAPK as
potential mediators of HSV sensitivity. Activation of STAT1 did not
increase significantly after virus infection, whereas p38 MAPK
activation did increase after treatment. These features have been
shown to be favorable for HSV infection by our group and other
investigators [21,23,24] and may at least partially explain the
sensitivity of the RMS cell lines to M002.
The current studies showed that combining low-dose ionizing
radiation with the administration of M002 enhanced the inhibitory
effects of M002 on RMS xenograft tumor growth. Previous authors
have noted that radiotherapy acts synergistically with other oHSVs
[30–33]. Chung and colleagues reported that combining ionizing
radiation with R7020 recombinant HSV caused a greater reduction in
hepatoma xenografts than either radiation or virus alone [34].
Andusumulli and colleagues showed that oHSV NV1066 when
combined with 5-Gy external beam radiation significantly reduced
H1299 lung xenograft tumors when compared with either modality
alone [32]. In translating this therapy to the clinical setting, our
current findings are exceedingly relevant. Radiotherapy is currently
included in the treatment regimen for RMS, and the findings from
this study demonstrated that combining both modalities for upfront
therapy may allow for significant dose reduction in both therapies,
leading to potentially decreased therapy-related toxicities. In recurrent
disease, tumors may be accessible by radiologic-guided percutaneous
interventions, allowing for easier repeated dosing of the virus. Finally,
studies are currently being conducted investigating the efficacy of
systemic administration of oHSV.
The trends in median xenograft tumor weights were similar to the
trends noted in tumor volumes. The final weight of the xenografts
from the SJCRH30 cell line treated with M002 and XRT was
significantly different from that of xenografts treated with vehicle and
XRT but not vehicle alone. This finding may be secondary to the
timing of the determination of the weight of the xenografts. The
xenografts were weighed at the time of euthanasia, which was dictated
by tumor volume reaching IACUC parameters.
In summary, in these studies, we have shown for the first time that
multiple injections of oHSV M002 to human xenograft models of
RMS resulted in a significant decrease in tumor growth, and radiation
augmented this effect. Other novel aspects of this study were the
demonstration that multiple oHSV entry molecules were present in
the RD and SJCRH30 cell lines and that human RMS tumor
specimens express CD111, a key HSV entry molecule. These findings
suggest that the humanized form of oHSV, M032, which is currently
being studied in a phase I trial in adults with recurrent glioblastoma
(clinicaltrials.gov identifier NCT02062827), may have therapeutic
potential for these difficult-to-treat pediatric solid tumors.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2016.07.008.
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